FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS ...

Meet 5 hot biotechs in Arizona, from Phoenix to Tucson, that have raised significant funding over the past decade.

Jacobio Pharma(HKEX: 1167) today announced its annual results for the year ended Dec. 31, 2025, and provided updates on its key pipeline programs. During 2025, the company achieved several key ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...

Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside. ・MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones ...

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that ...

Dr. Kevin Kalinsky discusses common side effects associated with the FDA-approved combination of Enhertu and Perjeta for breast cancer.

Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will ...

Uğur Şahin, M.D., who is currently the CEO of BioNTech, and his wife Özlem Türeci, M.D., who is chief medical officer, founded mRNA-focused BioNTech in 2008. The company rose to prominence and ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...